170 related articles for article (PubMed ID: 15540903)
1. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
Ogura M; Morishima Y; Kobayashi Y; Uike N; Sugai S; Chou T; Kasai M; Miura I; Murayama T; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Tobinai K;
Int J Hematol; 2004 Oct; 80(3):267-77. PubMed ID: 15540903
[TBL] [Abstract][Full Text] [Related]
2. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
3. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.
Saven A; Emanuele S; Kosty M; Koziol J; Ellison D; Piro L
Blood; 1995 Sep; 86(5):1710-6. PubMed ID: 7655003
[TBL] [Abstract][Full Text] [Related]
4. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.
Tobinai K; Watanabe T; Tanimoto K; Maruyama D; Nakata M; Itoh K; Morishima Y; Ogura M; Usui N; Kasai M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y
Cancer Sci; 2009 Jul; 100(7):1344-50. PubMed ID: 19432900
[TBL] [Abstract][Full Text] [Related]
6. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.
Tobinai K; Uike N; Saburi Y; Chou T; Etoh T; Masuda M; Kawano F; Matsuoka M; Taguchi H; Makino T; Asano Y; Tamura K; Ohashi Y;
Int J Hematol; 2003 Jun; 77(5):512-7. PubMed ID: 12841391
[TBL] [Abstract][Full Text] [Related]
8. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
[TBL] [Abstract][Full Text] [Related]
9. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
[TBL] [Abstract][Full Text] [Related]
10. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
Robak T; Smolewski P; Urbanska-Rys H; Gora-Tybor J; Blonski JZ; Kasznicki M
Leuk Lymphoma; 2004 May; 45(5):937-44. PubMed ID: 15291352
[TBL] [Abstract][Full Text] [Related]
11. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.
Rummel MJ; Chow KU; Jäger E; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
Ann Oncol; 1999 Jan; 10(1):115-7. PubMed ID: 10076731
[TBL] [Abstract][Full Text] [Related]
12. Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma.
Liliemark J; Porwit A; Juliusson G
Leuk Lymphoma; 1997 Apr; 25(3-4):313-8. PubMed ID: 9168441
[TBL] [Abstract][Full Text] [Related]
13. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.
Hoffman M; Tallman MS; Hakimian D; Janson D; Hogan D; Variakogis D; Kuzel T; Gordon LI; Rai K
J Clin Oncol; 1994 Apr; 12(4):788-92. PubMed ID: 7908690
[TBL] [Abstract][Full Text] [Related]
14. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
Robak T; Lech-Maranda E; Janus A; Blonski J; Wierzbowska A; Gora-Tybor J
Leuk Lymphoma; 2007 Jun; 48(6):1092-101. PubMed ID: 17577772
[TBL] [Abstract][Full Text] [Related]
15. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.
Rummel MJ; Chow KU; Jäger E; Leimer L; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
Leuk Lymphoma; 1999 Sep; 35(1-2):129-38. PubMed ID: 10512170
[TBL] [Abstract][Full Text] [Related]
16. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma.
Saven A; Lee T; Kosty M; Piro L
J Clin Oncol; 1996 Jul; 14(7):2139-44. PubMed ID: 8683247
[TBL] [Abstract][Full Text] [Related]
17. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
Bennani NN; LaPlant BR; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic SN; Nowakowski GS; Macon WR; Reeder CB; Mikhael JR; Northfelt DW; Ghobrial IM; Witzig TE
Am J Hematol; 2017 May; 92(5):448-453. PubMed ID: 28211162
[TBL] [Abstract][Full Text] [Related]
19. Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study.
Takamatsu Y; Suzumiya J; Ogata K; Katayose K; Sasaki H; Ishitsuka K; Kimura N; Tamura K
J Clin Exp Hematop; 2009 Nov; 49(2):69-75. PubMed ID: 19907111
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
